IBD & CKD: Kidney-Safe Treatment Guide for Prescribers

The intersection of inflammatory bowel disease (IBD) and chronic kidney disease (CKD) is becoming an increasingly critical area of focus for clinicians, and a recent review article published in Aliment Pharmacol Ther provides urgently needed guidance. This isn’t merely an academic exercise; the rising prevalence of both IBD and CKD – driven by aging populations and lifestyle factors – means more patients are presenting with these co-morbidities, demanding a more nuanced approach to treatment. The review underscores that while most IBD therapies appear safe even in advanced kidney disease, careful consideration and, in some cases, dose adjustments are essential to protect vulnerable renal function.

The increasing co-occurrence of IBD and CKD isn’t surprising. Both conditions share inflammatory pathways and risk factors, and the systemic inflammation inherent in IBD can directly contribute to kidney damage. Furthermore, some IBD medications themselves can have nephrotoxic effects, or require renal metabolism for clearance. This review serves as a vital resource for gastroenterologists and nephrologists alike, highlighting the need for collaborative care and a deep understanding of pharmacokinetics in this patient population.

The review meticulously breaks down recommendations for each major class of IBD medication. For corticosteroids, the guidance emphasizes utilizing the lowest effective dose for the shortest duration, acknowledging that dose adjustments aren’t typically needed in advanced kidney disease, but suggesting budesonide over prednisolone to minimize systemic effects. Aminosalicylates require regular renal function monitoring and adequate hydration. Immunomodulators like thiopurines and methotrexate necessitate dose adjustments based on estimated glomerular filtration rate (eGFR), with methotrexate being largely avoided in end-stage kidney disease (ESKD) due to toxicity concerns. Importantly, the review confirms the generally favorable safety profile of biologics, often eliminating the need for dose adjustments based on renal function, though vigilance for rare autoimmune renal complications is advised.

However, the most significant caution flags are raised regarding Janus kinase (JAK) inhibitors. With limited data available, dose reduction is recommended in advanced renal disease. This highlights a critical gap in our knowledge and underscores the need for further research into the long-term renal effects of these newer IBD therapies.

The Forward Look: The publication of these guidelines is likely to prompt a shift towards more proactive renal monitoring in IBD patients, particularly those with pre-existing CKD. We can anticipate increased adoption of eGFR-based dose adjustments for medications like thiopurines and JAK inhibitors. More importantly, this review will likely fuel further research into the optimal management of IBD in patients with CKD, including clinical trials specifically designed to assess the renal safety of newer therapies. The development of more renal-sparing IBD treatments is now a clear priority, and we can expect to see pharmaceutical companies investing in this area. Finally, expect to see increased emphasis on multidisciplinary care models, bringing gastroenterologists and nephrologists together to provide comprehensive care for these complex patients. The focus will be on personalized medicine, tailoring treatment strategies to individual patient profiles and minimizing the risk of renal compromise.

Reference

Chen L, Srinivasan A, Choy SW, Van J, Habeeb H, Nguyen A, Vasudevan A. Prescribing inflammatory bowel disease medications in chronic kidney disease: a practical guide. Aliment Pharmacol Ther. 2025;62(4):400-418. doi:10.1111/apt.70262